Human Insulin Market, By Product Types (Basal or Long-acting Insulins (Lantus, Levemir, Toujeo, Tresiba, and Basagla), Bolus or Fast-acting Insulins (NovoRapid/Novolog, Humalog, Apidra, FIASP, and Admelog), Traditional Human Insulins (Novolin/Actrapid/Insulatard, and Humulin, Insuman), Combination Insulins (NovoMix, Ryzodeg, Xultophy, and Soliqua/Suliqua), and Biosimilar Insulins (Insulin Glargine Biosimilars, and Human Insulin Biosimilars)) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI390320 | Publish Date: August 2023 | No. of Pages: 163

Global Human Insulin Market By Overview

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood.  Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. The Human Insulin Market accounted for US$ 22.97 billion in 2020 and is estimated to be US$ 35.01 billion by 2030 and is anticipated to register a CAGR of 4.3%.

Global Human Insulin Market By Dynamics

                                                             

Rising prevalence of diabetes

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin. With the growing need for human insulin this market consist various opportunities such as application of regulations against needle anxiety, needle stick injuries, and rising awareness related to the danger of blood borne pathogen transmission. Additionally, increasing demand for biosimilar drugs because they are cost effective that are considered as the growth drivers for the global human insulin market. However, limited access to human insulin in emerging economies and uneven pricing may affect the target market growth.

Moreover, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Nevertheless, with growing effort for in healthcare sector by government and various organization may help in overcoming these limitations.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Human Insulin Market By Segmentation

                              

The global human insulin market is segmented based on product type, and region.

Based on product type, the global human insulin market is segmented into first-basal or long-acting insulins which is further segmented on the basis of brands Lantus, Levemir, Toujeo, Tresiba, and Basagla, second-bolus or fast-acting insulins which is categorized on the basis of brands NovoRapid/Novolog, Humalog, Apidra, FIASP, and Admelog, third-traditional human insulins is divided into Novolin/Actrapid/Insulatard, Humulin, and Insuman, fourth-combination insulins is separated into NovoMix, Ryzodeg, Xultophy, and Soliqua/Suliqua, and fifth-biosimilar insulins Insulin Glargine Biosimilars, and Human Insulin Biosimilars. Biosimilar drugs were likely to add up for the biggest market share of the global human insulin market and are expected to stay the same in the near future. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs.

Regional Insights:

                                     

Based on the region the global human insulin market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the global human insulin market due to growing demand for advanced medical technologies and increasing geriatric population. Asia Pacific human insulin market is projected to register a high CAGR over the forecast period owing to the growing trend of high prevalence of diabetes and technological advances in effective insulin delivery.

                                   

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Product Type- Basal or Long-Acting, Bolus or fast-Acting, Traditional Human Insulin, Combination Insulin and Biosimilar Insulin

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Global Human Insulin Market, By Product Type:

  • Basal or Long-acting Insulins
    • Lantus
    • Levemir
    • Toujeo
    • Tresiba
    •  Basagla
  • Bolus or Fast-acting Insulins
    • NovoRapid/Novolog
    • Humalog
    • Apidra
    • FIASP
    • Admelog
  • Traditional Human Insulins
    • Novolin/Actrapid/Insulatard
    • Humulin
    • Insuman
  • Combination Insulins
    • NovoMix
    • Ryzodeg
    • Xultophy
    •  Soliqua/Suliqua
  • Biosimilar Insulins
    • Insulin Glargine Biosimilars,
    • Human Insulin Biosimilars

Global Human Insulin Market, By Region:

      • North America
        • North America Human Insulin  Market, By Product Type
        • North America Human Insulin  Market, By Country
          • U.S.
          • Canada
      • Europe
        • Europe Human Insulin  Market, By Product Type
        • Europe Human Insulin  Market, By Country
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
        • Asia Pacific Human Insulin  Market, By Product Type
        • Asia Pacific Human Insulin  Market, By Country
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
        • Latin America Human Insulin  Market, By Product Type
        • Latin America Human Insulin  Market, By Country
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
        • Middle East & Africa Human Insulin  Market, By Product Type
        • Middle East & Africa Human Insulin  Market, By Country
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Human Insulin Market By Key Players

Key Players:

                                                                        

The key players operating the global human insulin market involves Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, and GalxoSmithCline. In June 2018, Humulin R U-500 of Eli Lilly and Company, which was utilized in insulin pumps, showed better A1C lowering in people with type 2 diabetes. This was deemed great when compared to multiple daily injections, thus boosting the expansion of global human insulin market. Novo Nordisk is developing a first once-weekly long-acting insulin (LAI287) which is currently in phase 2. The insulin is indicated for both type-1 and type-2 diabetes patients.

Global Human Insulin Market By Company Profile

      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Biocon
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Adocia
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Wockhardt
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • GlaxoSmithKline
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance

Global Human Insulin Market By Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Industry Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Human Insulin  Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Product Type
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Human Insulin  Market, By Product Type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Basal or Long-acting Insulins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
      • Lantus
      • Levemir
      • Toujeo
      • Tresiba
      •  Basagla
    • Bolus or Fast-acting Insulins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
      • NovoRapid/Novolog
      • Humalog
      • Apidra
      • FIASP
      • Admelog
    • Traditional Human Insulins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
      • Novolin/Actrapid/Insulatard
      • Humulin
      • Insuman
    • Combination Insulins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
      • NovoMix, Ryzodeg, Xultophy
      • Soliqua/Suliqua
    • Biosimilar Insulins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
      • Insulin Glargine Biosimilars
      • Human Insulin Biosimilars
  6. Global Human Insulin  Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Products Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Products Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Products Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Products Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  8. Company Profiles
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Biocon
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Tonghua Dongbao Pharmaceutical Co., Ltd
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Adocia
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Wockhardt
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • GalxoSmithCline
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
  9. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The global human insulin market is segmented based on product type, and region.

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services.

The market in North America accounts highest revenue share to the global human insulin market due to growing demand for advanced medical technologies and increasing geriatric population.

The key players operating the global human insulin market involves Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, and GalxoSmithCline.